For the first time in the modern history of Kazakhstan, domestic scientists have published the results of phase III extensive clinical trials of the first Kazakh vaccine QazVac against coronavirus infection COVID-19, in the journal of the LANCET family, these are scientific journals with the highest world ranking in the field of medicine.
The article “Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in, in healthy adults: A multicentre, randomized, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up” was published today in the journal EClinicalMedicine, part of The Lancet group, with the results of phase III broad multicenter clinical trials of the QazVac vaccine against COVID-19.
As part of the scientific and technical program “Development of a vaccine against COVID-19 coronavirus infection”, the QazVac vaccine against COVID-19 was developed at the Research Institute of Biological Safety Problems of the Ministry of Health of the Republic of Kazakhstan, under the leadership of the Director General of RIBSP, Doctor of Biological Sciences, Professor Kunsulu Zakarya. According to the positive results of preclinical trials, in accordance with the protocol of clinical trials, the Ministry of Health of the Republic of Kazakhstan and the recommendations of the World Health Organization, phase III clinical trials were conducted to study safety, immunogenicity, and other parameters. The results of the tests have shown the effectiveness and safety of the vaccine for humans, as well as the formation of high immunity.
EClinicalMedicine is the journal of The Lancet group, publishes the results of original research in the field of medicine and healthcare, as well as the latest achievements in the development and research of vaccines against COVID-19.
Domestic scientists of the Research Institute of Biological Safety Problems of the Ministry of Health of the Republic of Kazakhstan make a feasible contribution to the development of science in Kazakhstan, the fight against a new infection of the 21st century.